News

Filter

Current filters:

RituxanNorth America

1 to 9 of 11 results

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch

25-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

US rheumatologists continue to increase use of biologics for RA treatment

29-03-2012

Biologic agents remain the preferred treatment for patients suffering from rheumatoid arthritis (RA),…

ActemraAnti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingNorth AmericaOrenciaPharmaceuticalRituxantofacitinib

Roche gets FDA OK for use of Rituxan to treat two rare disorders

21-04-2011

The US Food and Drug Administration yesterday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech’s…

North AmericaPharmaceuticalRare diseasesRegulationRituxanRoche

Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint

31-01-2011

Swiss drug major Roche’s (ROG: VX) subsidiary Genentech and Biogen Idec (Nasdaq: BIIB) on Friday…

Biogen IdecBiotechnologyGenentechNorth AmericaOncologyPharmaceuticalRegulationResearchRituxanRocheTarceva

1 to 9 of 11 results

COMPANY SPOTLIGHT

Menarini

Back to top